Changchun High-tech: Subsidiary GenSci134 injection clinical trial application accepted.

Changchun High-tech announced on the evening of August 26 that its subsidiary, Jinsai Pharmaceutical, recently received the "Acceptance Notice" issued by the National Medical Products Administration. Jinsai Pharmaceutical's GenSci134 injection, a domestically produced drug for clinical trial registration, has been accepted. GenSci134 is a type 1 biological product developed independently by Jinsai Pharmaceutical, intended for the treatment of growth hormone deficiency, including adult growth hormone deficiency, pediatric growth hormone deficiency, and the treatment of non-GHD patients. This application targets children with slow growth and idiopathic short stature caused by endogenous growth hormone deficiency.